Loading...
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
BACKGROUND: High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemistry (IHC...
Na minha lista:
Udgivet i: | Genome Med |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
BioMed Central
2017
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5395719/ https://ncbi.nlm.nih.gov/pubmed/28420421 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-017-0424-2 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|